Dana Brown

Dana Brown is deputy director of The Next System Project at the Democracy Collaborative.

Recent Articles

Before Big Pharma Kills Us, Maybe Public Pharma Can Save Us

Drug companies are abandoning antibiotic research to make more money elsewhere. Yet another reason why we need a publicly owned company.

Victor Moussa/Shutterstock D rug-resistant “superbugs” are predicted to kill more people per year than cancer by 2050. Already, more than two million Americans annually are infected with bacteria that have evolved to resist antibiotics with at least 23,000 dying as a result . Given the nature of infectious disease, antibiotic resistance is increasingly seen as a threat to national security , with potential consequences for trade, global development, and even counterterrorism . Despite the many incentives being thrown their way, however, major pharmaceutical companies are pulling out of antibiotic research and development at alarming rates , citing a lack of market incentives. In an industry that has a bad case of market-incentive syndrome, it is time to consider the establishment of public pharmaceutical companies as an antidote. The increasing threat of superbugs arises in large part because antibiotic resistance is growing while the development of new antibiotics is on the decline...